Prometheus Biosciences, Inc.

RXDXCIK 0001718852 · Every Form 4 filed by insiders at this issuer. See financials →

Annual report (10-K)

Latest 10-K/A filed Apr 28, 2023. Sentiment + YoY language diff vs prior year. Read sections →

Signal:NeutralFull-doc fallback

Full filing:tone -0.0017

Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.

YoY shift: Unscored

Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.

Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.

Per-snippet highlights

Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.

Top insiders

Most active reporters at Prometheus Biosciences, Inc.

Name	Roles	Filings
Marshall Keith W	Officer	7
McKenna Mark C.	OfficerDirector	7
Papa Joseph C	Director	4
Adams Helen C.	Director	3
Hassan Fred	Director	3

Showing 1-5 of 11

Per pagePage 1 of 3Next

All filings

41 Form 4 / 4-A filings, newest first

Filed	Insider	Top transaction	Shares	Price	Value
May 20, 2022	McKenna Mark C. Chairman, President & CEO · Director	Holdings only	-	-	-
May 20, 2022	Marshall Keith W Chief Financial Officer	Holdings only	-	-	-
May 20, 2022	Stenhouse Mark Chief Operating Officer	Holdings only	-	-	-
May 20, 2022	Adams Helen C. Director	Holdings only	-	-	-
May 20, 2022	Hassan Fred Director	Holdings only	-	-	-

Showing 31-35 of 41

Per pagePrevPage 7 of 9Next

Real-time Form 4 intelligence. Smarter insider tracking.

Filed		Top transaction	Shares	Price	Value